2型糖尿病患者使用他汀类药物与癌症发病率：一项网状Meta分析
Statin Use and Cancer Incidence in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis.
作者信息
Hu Yi-Bing, Hu En-De, Fu Rong-Quan
机构信息
Department of Gastroenterology and Hepatology, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, Jinhua, 321000 Zhejiang, China.
Department of Anesthesiology, Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000 Zhejiang, China.
出版信息
Gastroenterol Res Pract. 2018 Sep 4;2018:8620682. doi: 10.1155/2018/8620682. eCollection 2018.
BACKGROUND
Type 2 diabetes mellitus (T2DM) patients are involved closely with cancer. This work aims to conduct a systematic review and network meta-analysis (NMA) to examine the effect of different types of statins on cancer incidence in patients with T2DM.
METHODS
We systematically searched the Cochrane Library, PubMed, Embase, and Wanfang databases from January 1999 to March 2017. We performed a pairwise meta-analysis to estimate the pooled ratios (ORs) and 95% confidence intervals (CIs). A NMA was performed to compare different types of statins.
RESULTS
Seven publications were included. In pairwise meta-analysis, the incidence of cancer in T2DM patients was reduced when simvastatin, atorvastatin, pravastatin, fluvastatin, lovastatin, rosuvastatin, and pitavastatin were used. In the result of NMA, the usage of simvastatin (RR 0.30 and 95% CI 0.16-0.56), atorvastatin (RR 0.29 and 95% CI 0.09-0.88), pravastatin (RR 0.34 and 95% CI 0.12-0.93), fluvastatin (RR 0.27 and 95% CI 0.09-0.83), rosuvastatin (RR 0.22 and 95% CI 0.10-0.49), and pitavastatin (RR 0.33 and 95% CI 0.20-0.57) was superior to the nonstatin groups. When compared with six other statins, rosuvastatin appeared to be the best one.
CONCLUSIONS
Different statins can reduce the risk of cancer in patients with T2DM. Our analyses suggest that rosuvastatin may be more effective than others.
背景
2型糖尿病（T2DM）患者与癌症密切相关。本研究旨在进行一项系统评价和网状Meta分析（NMA），以探讨不同类型他汀类药物对T2DM患者癌症发病率的影响。
方法
我们系统检索了1999年1月至2017年3月的Cochrane图书馆、PubMed、Embase和万方数据库。我们进行了两两Meta分析以估计合并比值比（OR）和95%置信区间（CI）。进行NMA以比较不同类型的他汀类药物。
结果
纳入7篇文献。在两两Meta分析中，使用辛伐他汀、阿托伐他汀、普伐他汀、氟伐他汀、洛伐他汀、瑞舒伐他汀和匹伐他汀时，T2DM患者的癌症发病率降低。在NMA结果中，使用辛伐他汀（RR 0.30，95%CI 0.16 - 0.56）、阿托伐他汀（RR 0.29，95%CI 0.09 - 0.88）、普伐他汀（RR 0.34，95%CI 0.12 - 0.93）、氟伐他汀（RR 0.27，95%CI 0.09 - 0.83）、瑞舒伐他汀（RR 0.22，95%CI 0.10 - 0.49）和匹伐他汀（RR 0.33，95%CI 0.20 - 0.57）优于非他汀类药物组。与其他六种他汀类药物相比，瑞舒伐他汀似乎是最佳选择。
结论
不同的他汀类药物可降低T2DM患者患癌风险。我们的分析表明，瑞舒伐他汀可能比其他药物更有效。
Zotero 插件